HomeCompareSSYNF vs MO

SSYNF vs MO: Dividend Comparison 2026

SSYNF yields 1000000.00% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SSYNF wins by $4.7683925249533696e+36M in total portfolio value
10 years
SSYNF
SSYNF
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full SSYNF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — SSYNF vs MO

📍 SSYNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSYNFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSYNF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSYNF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSYNF
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, SSYNF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSYNF + MO for your $10,000?

SSYNF: 50%MO: 50%
100% MO50/50100% SSYNF
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SSYNF
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSYNF buys
0
MO buys
0
No recent congressional trades found for SSYNF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSYNFMO
Forward yield1000000.00%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$4.7683925249533696e+36M$80.1K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,159.17
Total dividends collected$4.7683311610149396e+36M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SSYNF vs MO ($10,000, DRIP)

YearSSYNF PortfolioSSYNF Income/yrMO PortfolioMO Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,570$780.30+$100.00MSSYNF
2$934,786,450,701$934,679,439,252.34$11,381$1,032.90+$934786.44MSSYNF
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,535$1,392.73+$8165787108.57MSSYNF
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$14,193$1,920.91+$66665884190957.63MSSYNF
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$16,618$2,723.68+$508662171058048128.00MSSYNF
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$20,263$3,993.80+$3.62723524842849e+21MSSYNF
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$25,936$6,098.36+$2.417368115915061e+25MSSYNF
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$35,166$9,775.01+$1.5056740286145463e+29MSSYNF
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$51,026$16,597.78+$8.764771002818475e+32MSSYNF
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$80,113$30,159.17+$4.7683925249533696e+36MSSYNF

SSYNF vs MO: Complete Analysis 2026

SSYNFStock

Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm. Sensyne Health has strategic research alliance with Bayer and Roche; collaboration agreement with Alexion to study the prevalence and outcomes of patients in certain disease areas; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; research agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma; strategic research agreement with Milton Keynes University Hospital, Somerset, Hampshire, Royal Wolverhampton, and Royal Devon and Exeter NHS Trusts. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

Full SSYNF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SSYNF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSYNF vs SCHDSSYNF vs JEPISSYNF vs OSSYNF vs KOSSYNF vs MAINSSYNF vs PMSSYNF vs BTISSYNF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.